Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology

Introduction

Moroz and colleagues situate their paper at the intersection of two emerging therapeutic technologies: highly immersive virtual reality (VR) and renewed research into psychedelic medicines. They note that both modalities individually have shown promise for treating a range of psychiatric disorders—examples cited include psilocybin and LSD for depression and anxiety, ketamine for rapid antidepressant effects, and MDMA for PTSD—and argue that VR similarly offers therapeutic potential because it can reliably manipulate sensory input to evoke immersion and presence. The authors emphasise that both approaches are constrained by setting and stimulus control, and they highlight a conceptual gap: prior work has considered VR and psychedelics separately rather than as intentionally combined interventions that might interact synergistically. The paper sets out to propose and reason through a composite therapeutic approach that deliberately combines VR and psychedelics. The central hypothesis is that such a fusion will yield three principal benefits: (1) synergistic increases in the efficacy of each modality through mutual enhancement, (2) greater specificity by tailoring virtual environments to individual pathologies, and (3) the possibility of achieving therapeutic effects using lower psychedelic doses. The authors suggest that these combined interventions could be particularly valuable for disorders where specific sensory stimulation and maximal immersion are therapeutically important.